RT Journal Article
T1 Resveratrol supplementation: Where are we now and where should we go?
A1 Garrido Novelle, Marta
A1 Wahl, Devin
A1 Diéguez, Carlos
A1 Bernier, Michel
A1 De Cabo, Rafael
AB Pre-clinical findings have provided mounting evidence that resveratrol, a dietary polyphenol, may confer health benefits and protect against a variety of medical conditions and age-related complications. However, there is no consistent evidence of an increased protection against metabolic disorders and other ailments when comparing studies in laboratory animals and humans. A number of extraneous and potential confounding variables can affect the outcome of clinical research. To date, most of the studies that have investigated the effect of resveratrol administration on patient outcomes have been limited by their sample sizes. In this review, we will survey the latest advances regarding the timing, dosage, formulation, bioavailability, toxicity of resveratrol, and resveratrol–drug interactions in human studies. Moreover, the present report focuses on the actions of resveratrol treatment in combating diseases, such as cancer, diabetes, neurodegeneration, cardiovascular disease, and other age-related ailments.
PB Elsevier
SN 1568-1637
YR 2015
FD 2015
LK https://hdl.handle.net/20.500.14352/94838
UL https://hdl.handle.net/20.500.14352/94838
LA eng
NO This work has been supported by the Intramural Research Program of the National Institute on Aging, National Institutes of Health. CIBER de Fisiopatología de la Obesidad y Nutrición is an initiative of ISCIII.
NO National Institutes of Health
NO Instituto de Salud Carlos III
DS Docta Complutense
RD 8 abr 2025